Risk factors for subsequent thyroid neoplasm development in childhood cancer survivors
Endocrine-Related Cancer · 2026
DOI: 10.1530/erc-26-0210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2026. Verfasst von Dana Nováková und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Endocrinology, 2nd Faculty of Medicine, Charles University and Motol and Homolka University Hospital , Prague, Cze…. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Cancer Survivors, Neoplasms, Second Primary. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Subsequent thyroid carcinomas (STCs) are common after childhood cancer treatment and have well-described risk factors, whereas information on subsequent thyroid adenomas (STAs) remains limited. This study compared treatment-related risk factors for STCs and STAs, assessed their associations with other subsequent neoplasms, and evaluated the incidence of STCs relative to that in the age-matched national general population. The study cohort included 4,348 childhood cancer survivors treated between 1975 and 2020; 48% were female, 23% had lymphomas, and 77% had solid tumors. STCs occurred in 44 survivors (59% female), and STAs occurred in 23 (65% female). Compared with the national general population, the risk of STCs was 7.6-fold higher in females and 23.6-fold higher in males. The median age at diagnosis was lower for STCs (25.8 vs 29.8 years). Hodgkin lymphoma was the most frequent primary cancer in both groups (48% vs 57%). The median age at first cancer diagnosis was similar between the groups (9.8 vs 9.4 years). Neck radiotherapy was a major risk factor in both groups (59% vs 83%). Additional subsequent malignant neoplasms occurred in 14% of patients with STCs and 13% of patients with STAs, whereas subsequent benign neoplasms occurred in 20% and 26%, respectively. The incidence of subsequent benign neoplasms was higher in patients with STCs than in patients with other first subsequent malignant neoplasms (P < 0.05). STCs predominated over STAs (66%). Shared risk factors included neck radiotherapy and Hodgkin lymphoma. STCs were diagnosed at a younger age. The frequent occurrence of additional subsequent neoplasms highlights the need for long-term surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine and Endocrinology, 2nd Faculty of Medicine, Charles University and Motol and Homolka University Hospital , Prague, Czech Republic.
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol and Homolka University Hospital , Prague, Czech Republic.
- Department of Ear, Nose and Throat, 2nd Faculty of Medicine, Charles University and Motol and Homolka University Hospital , Prague, Czech Republic.
- Department of Oncology, 2nd Faculty of Medicine, Charles University and Motol and Homolka University Hospital , Prague, Czech Republic.
ORCID-Profile: Jarmila Kruseová
Zitieren
APA
Nováková, D., Švojgr, K., Katra, R., Bartůňková, T., Vlček, P., Kindlová, A., Jirkovská, M., Blagodárná, S., Eckschlager, T., Šrámková, L., & Kruseová, J. (2026). Risk factors for subsequent thyroid neoplasm development in childhood cancer survivors. Endocrine-Related Cancer. https://doi.org/10.1530/erc-26-0210
Vancouver
Nováková D, Švojgr K, Katra R, Bartůňková T, Vlček P, Kindlová A, et al. Risk factors for subsequent thyroid neoplasm development in childhood cancer survivors. Endocrine-Related Cancer. 2026. doi:10.1530/erc-26-0210
BibTeX
@article{Novkov2026,
author = {Nováková, Dana and Švojgr, Karel and Katra, Rami and Bartůňková, Tereza and Vlček, Petr and Kindlová, Anna and Jirkovská, Michaela and Blagodárná, Sarah and Eckschlager, Tomáš and Šrámková, Lucie and Kruseová, Jarmila},
title = {Risk factors for subsequent thyroid neoplasm development in childhood cancer survivors},
journal = {Endocrine-Related Cancer},
year = {2026},
doi = {10.1530/erc-26-0210}
}
EUVIMED